Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Darmstadt – page 5

93 clinical trials in Darmstadt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Darmstadt at a glance
93
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

93 trials in Darmstadt

Open in trial search

Dermatitis atopic

Not recruiting

Study on the Long-term Safety and Effectiveness of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG

Dermatitis atopic+1

Not recruiting

Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Glucocorticoids
  • Sponsor:Eli Lilly & Co.

Skin wrinkling

Not recruiting

Corabotase for Moderate to Severe Glabellar Lines in Adults

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Study of tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

Hidradenitis

Not recruiting

Study of Tibulizumab to Treat Adults with Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tibulizumab
  • Sponsor:Zura Bio Inc.

Hidradenitis

Not recruiting

Study of ruxolitinib cream for treating hidradenitis suppurativa in adult patients

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Hidradenitis

Not recruiting

Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Asthma

Not recruiting

Study on GSK5784283 for Adults Aged 18-75 with Uncontrolled Asthma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5784283
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Darmstadt

What the registry says about research in the country

01 Dermatology Studies

Extensive research focusing on plaque psoriasis and hidradenitis suppurativa, evaluating new therapeutic approaches for chronic skin conditions. Multiple trials are testing novel treatments for moderate to severe cases.

  • Psoriasis Management
  • Hidradenitis Suppurativa Treatment
  • Atopic Dermatitis Therapy

Several innovative compounds being tested including ESK-001, remibrutinib, and JNJ-77242113.

02 Respiratory Medicine

Comprehensive studies addressing severe asthma and COPD, with particular attention to treatments for patients with eosinophilic phenotypes and those requiring advanced care options.

  • Asthma Control
  • COPD Management
  • Chronic Cough Treatment

Trials evaluating new inhalation therapies and biological treatments for better disease control.

03 Oncology Research

Advanced studies in acute myeloid leukemia, investigating combination therapies for patients ineligible for intensive chemotherapy. Focus on targeted treatments for specific genetic mutations.

  • AML Treatment
  • Novel Drug Combinations
  • Targeted Therapies

Investigating innovative approaches including revumenib in combination with established treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.